Please assess the completion status of the following clinical trial:

Trial Title: Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient meets protocol specified criteria for constipation~* Patient has successfully completed study requirements with no clinically relevant findings for physical exam, ECG, laboratory tests and colonoscopy as applicable~Exclusion Criteria:~* Medical history or medical condition that would not make the patient a good candidate for the study or limit the patient´s ability to complete the study~* Patient reports loose stools~* Patient has IBS with pain/discomfort as predominant symptom~* Patient needs medications prohibited as specified in the protocol

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A3309 low dose (Type: EXPERIMENTAL): Administered once daily for the duration of the study
- A3309 intermediate dose (Type: EXPERIMENTAL): Administered once daily for the duration of the study.
- A3309 high dose (Type: EXPERIMENTAL): Administered once daily for the duration of the study
- Placebo (Type: PLACEBO_COMPARATOR): Administered once daily for the duration of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).